CollPlant Biotechnologies (CLGN)
(Delayed Data from NSDQ)
$6.63 USD
-0.12 (-1.81%)
Updated May 10, 2024 12:37 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for CollPlant Biotechnologies Ltd Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 27 | 30 | 43 | 3 | 4 |
Receivables | 0 | 1 | 1 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 1 | 1 | 1 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 28 | 32 | 45 | 6 | 5 |
Net Property & Equipment | 3 | 3 | 3 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 34 | 38 | 51 | 11 | 11 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 1 | 1 | 2 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Total Current Liabilities | 3 | 3 | 3 | 3 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 5 | 6 | 6 | 7 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 5 | 5 | 5 | 3 | 2 |
Capital Surplus | 121 | 118 | 114 | 76 | 70 |
Retained Earnings | -97 | -90 | -73 | -73 | -67 |
Other Equity | -1 | -1 | -1 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 28 | 32 | 45 | 4 | 4 |
Total Liabilities & Shareholder's Equity | 34 | 38 | 51 | 11 | 11 |
Total Common Equity | 28 | 32 | 45 | 4 | 4 |
Shares Outstanding | 11.40 | 11.00 | 10.70 | 5.60 | 5.60 |
Book Value Per Share | 2.49 | 2.93 | 4.22 | 0.80 | 0.73 |
Fiscal Year End for CollPlant Biotechnologies Ltd Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 27 | 29 | 22 | 27 |
Receivables | NA | 0 | 1 | 10 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 1 | 2 | 2 | 2 |
Other Current Assets | NA | 0 | 0 | 1 | 0 |
Total Current Assets | NA | 28 | 31 | 35 | 29 |
Net Property & Equipment | NA | 3 | 3 | 3 | 3 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 34 | 38 | 42 | 36 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 1 | 1 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 3 | 3 | 3 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 6 | 5 | 6 | 6 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 5 | 5 | 5 | 5 |
Capital Surplus | NA | 121 | 120 | 120 | 119 |
Retained Earnings | NA | -97 | -92 | -88 | -93 |
Other Equity | NA | -1 | -1 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 28 | 32 | 36 | 30 |
Total Liabilities & Shareholder's Equity | NA | 34 | 38 | 42 | 36 |
Total Common Equity | 0 | 28 | 32 | 36 | 30 |
Shares Outstanding | 11.40 | 11.40 | 11.40 | 11.00 | 11.00 |
Book Value Per Share | 0.00 | 2.49 | 2.84 | 3.28 | 2.72 |